Brown, Tommy A., Kevin Byrd, Timothy J. Vreeland, Guy T. Clifton, Doreen O. Jackson, Diane F. Hale, Garth S. Herbert, et al. “Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.” Cancer Med 8, no. 10 (August 2019): 4678–87. https://doi.org/10.1002/cam4.2378.
Clifton, G Travis, Kaitlin M. Peace, Jarrod P. Holmes, Timothy J. Vreeland, Diane F. Hale, Garth S. Herbert, Jennifer K. Litton, et al. “Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.” Clin Immunol 201 (April 2019): 48–54. https://doi.org/10.1016/j.clim.2019.02.011.
Peace, K. M., G. S. Herbert, T. J. Vreeland, G. T. Clifton, and G. E. Peoples. “Therapeutic cancer vaccines for melanoma.” In Melanoma: A Modern Multidisciplinary Approach, 533–47, 2018. https://doi.org/10.1007/978-3-319-78310-9_33.
Herbert, Garth S., Timothy J. Vreeland, Guy T. Clifton, Julia M. Greene, Doreen O. Jackson, Mark O. Hardin, Diane F. Hale, et al. “Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.” Vaccine 36, no. 23 (May 31, 2018): 3247–53. https://doi.org/10.1016/j.vaccine.2018.04.078.
Vreeland, T. J., G. S. Herbert, and G. E. Peoples. “Cancer Vaccines for Solid Tumors.” In Immunotherapy in Translational Cancer Research, 72–90, 2018. https://doi.org/10.1002/9781118684535.ch6.
Hardin, Mark O., Timothy J. Vreeland, Guy T. Clifton, Diane F. Hale, Garth S. Herbert, Julia M. Greene, Doreen O. Jackson, et al. “Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine.” Immunotherapy 10, no. 5 (April 2018): 373–82. https://doi.org/10.2217/imt-2017-0114.
Herbert, Garth, Giorgos C. Karakousis, Edmund K. Bartlett, Salman Zaheer, Danielle Graham, Brian J. Czerniecki, Douglas L. Fraker, Charlotte Ariyan, Daniel G. Coit, and Mary S. Brady. “Transected thin melanoma: Implications for sentinel lymph node staging.” J Surg Oncol 117, no. 4 (March 2018): 567–71. https://doi.org/10.1002/jso.24930.
Berry, John, Timothy Vreeland, Alfred Trappey, Diane Hale, Kaitlin Peace, Joshua Tyler, Avery Walker, et al. “Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions.” Expert Review of Clinical Immunology 13, no. 3 (March 2017): 235–45. https://doi.org/10.1080/1744666x.2016.1226132.
Berry, J. S., T. J. Vreeland, D. F. Hale, D. O. Jackson, A. F. Trappey, J. M. Greene, M. O. Hardin, G. S. Herbert, G. T. Clifton, and G. E. Peoples. “Evaluation of attenuated tumor antigens and the implications for peptide-based cancer vaccine development.” Journal of Cancer 8, no. 7 (January 1, 2017): 1255–62. https://doi.org/10.7150/jca.16450.
Jackson, D. O., K. Byrd, T. J. Vreeland, D. F. Hale, G. S. Herbert, J. M. Greene, E. J. Schneble, et al. “Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.” Oncotarget 8, no. 9 (January 1, 2017): 15912–23. https://doi.org/10.18632/oncotarget.13305.